The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis
Abstract
BACKGROUND: Alefacept, human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein, binds to CD2 molecules on the surface of activated T cells, selectively targeting memory-effector (CD45RO+) T cells, which comprise more than 75% of T cells in psoriatic plaques. OBJECTIVE: To examine the efficacy and tolerability of intramuscular alefacept. DESIGN: International, randomized, double-blind, placebo-controlled, parallel-group trial. PATIENTS: A total of 507 patients with chronic plaque psoriasis. INTERVENTION: Placebo, 10 mg of alefacept, or 15 mg of alefacept administered once weekly for 12 weeks followed by 12 weeks of observation. MAIN OUTCOME MEASURE: Psoriasis Area Severity Index (PASI). RESULTS: Alefacept treatment was associated with dose-related significant improvements in PASI from baseline. Throughout the study, a greater percentage of patients in the 15-mg group than in the placebo group achieved a significant reduction in PASI. Of patients in the 15-mg group who achieved at least 75% PASI reduction 2 weeks after the last dose, 71% maintained at least 50% improvement in PASI throughout the 12-week follow-up. There were no opportunistic infections and no cases of disease rebound. CONCLUSION: Intramuscular administration of alefacept was a well-tolerated and effective therapy for chronic plaque psoriasis and thus represents a convenient alternative to intravenous dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
T-Cell Function and Migration — Two Sides of the Same Coin
von Andrian, U. H., & Mackay, C. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010053431407 · Cited by 1,437
Phenotypic and functional separation of memory and effector human CD8+ T cells
Hamann, D., Baars, P. A., Rep, M. H. G., Hooibrink, B., Kerkhof-Garde, S. R., Klein, M. R., & Lier, R. A. W. V. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.9.1407 · Cited by 1,366
Visualizing the generation of memory CD4 T cells in the whole body
Reinhardt, R. L., Khoruts, A., Merica, R., Zell, T., & Jenkins, M. K. (2001) · Nature · doi:10.1038/35065111 · Cited by 1,026 · cited 3×
“8) PGA score Severe 16 (10) 17 (10) 20 (12) 53 (10) Moderate to severe 66 (39) 64 (37) 53 (32) 183 (36) Moderate 62 (37) 70 (40) 65 (39) 197 (39) Mild to moderate 22 (13) 18 (10) 25 (15) 65 (13) Mild 2 (1) 4 (2) 3 (2) 9 (2) Most frequent prior therapy UV-B 82 (49) 80 (46) 71 (43) 233 (46) Psoralen–UV-A 67 (40) 71 (41)…”
Psoriasis − epidemiology and clinical spectrum
Christophers, E. (2001) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2001.00832.x · Cited by 972
Self-citationKrueger, G. G., Koo, J. Y. M., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001) · PubMed · Cited by 969
Self-citationSanders, M. E., Makgoba, M. W., Sharrow, S. O., Stephany, D., Springer, T. A., Young, H. A., & Shaw, S. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.5.1401 · Cited by 906
Lifespan of human lymphocyte subsets defined by CD45 isoforms
Michie, C. A., McLean, A., Alcock, C., & Beverley, P. C. L. (1992) · Nature · doi:10.1038/360264a0 · Cited by 636
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells
Fuhlbrigge, R. C., Kieffer, J. D., Armerding, D., & Kupper, T. S. (1997) · Nature · doi:10.1038/40166 · Cited by 577
Austin, L. M., Ozawa, M., Kikuchi, T., Walters, I. B., & Krueger, J. G. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00749.x · Cited by 485
Inflammatory Skin Diseases, T Cells, and Immune Surveillance
Robert, C., & Kupper, T. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412407 · Cited by 475
Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial
Ellis, C. N., Fradin, M. S., Messana, J. M., Brown, M. D., Siegel, M. T., Hartley, A. H., Rocher, L. L., Wheeler, S., Hamilton, T. A., Parish, T. G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240501 · Cited by 429
Comprehensive Dermatologic Drug Therapy
Wolverton, S. E. (2020) · Elsevier eBooks · doi:10.1016/c2014-1-02097-2 · Cited by 338
Krueger, G. G., Papp, K. A., Stough, D. B., Loven, K. H., Gulliver, W. P., & Ellis, C. N. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.127247 · Cited by 338
Hakim, F. T., Cepeda, R., Kaimei, S., Mackall, C. L., McAtee, N., Zujewski, J., Cowan, K., & Gress, R. E. (1997) · Blood · doi:10.1182/blood.v90.9.3789 · Cited by 323
FORTUNE, D. G., MAIN, C. J., O'SULLIVAN, T. M., & GRIFFITHS, C. E. M. (1997) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1997.19472062.x · Cited by 304
Self-citationThe pathogenesis of psoriasis: immunological facts and speculations
Bos, J. D., & De Rie, M. A. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01381-4 · Cited by 284
In vivo estimates of division and death rates of human T lymphocytes.
Mclean, A. R., & Michie, C. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3707 · Cited by 270 · cited 2×
“0 (6-85) 21 (6-95) PASI median (range) 14.”
Treatment of psoriasis. Part 1. Topical therapy and phototherapy
Lebwohl, M., & Ali, S. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117046 · Cited by 235
Self-citationThe impact of psoriasis on quality of life
de Arruda, L. H. F., & de Moraes, A. P. F. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.00034.x · Cited by 222
Bos, J. D., Hagenaars, C., Das, P. K., Krieg, S. R., Voorn, W. J., & Kapsenberg, M. L. (1989) · Archives of Dermatological Research · doi:10.1007/bf00424268 · Cited by 221
Dumont-Girard, F., Roux, E., van Lier, R. A., Hale, G., Helg, C., Chapuis, B., Starobinski, M., & Roosnek, E. (1998) · Blood · doi:10.1182/blood.v92.11.4464 · Cited by 220
Treatment of psoriasis. Part 2. Systemic therapies
Lebwohl, M., & Ali, S. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117047 · Cited by 199
Self-citationHamann, D., Kostense, S., Wolthers, K. C., Otto, S. A., Baars, P. A., Miedema, F., & van Lier, R. A. W. (1999) · International Immunology · doi:10.1093/intimm/11.7.1027 · Cited by 189
Miller, G. T., Hochman, P. S., Meier, W., Tizard, R., Bixler, S. A., Rosa, M. D., & Wallner, B. P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.211 · Cited by 170
Infections during low-dose methotrexate treatmentin rheumatoid arthritis
Boerbooms, A. M. T., Kerstens, P. J. S. M., van Loenhout, J. W. A., et al. (1995) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(95)80009-3 · Cited by 118
Fortune, D. G., Main, C. J., O'Sullivan, T., & Griffiths, C. E. M. (1997) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(97)00036-6 · Cited by 98
Self-citationFriedrich, M., Krammig, S., Henze, M., Döcke, W. ‐., Sterry, W., & Asadullah, K. (2000) · Archives of Dermatological Research · doi:10.1007/s004030000167 · Cited by 82
Baars, P. A., Ribeiro-do-Couto, L. M., Leusen, J. H. W., Hooibrink, B., Kuijpers, T. W., Lens, S. M. A., & van Lier, R. A. W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.4.1910 · Cited by 72
Meier, W., Gill, A., Rogge, M. C., Dabora, R. L., Gr, M., Fb, O., We, J., Frazier, D. E., Miatkowski, K., & Hochman, P. S. (1995) · PubMed · Cited by 50
Cited by
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Self-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citationAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Self-citationComparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Self-citationA Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T., & Lebwohl, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062382 · Cited by 807
Self-citation
Metadata
- Authors
- Lebwohl, M., Christophers, E., Langley, R., Ortonne, J. P., Roberts, J., & Griffiths, C. E. M.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-06-01
- Volume
- 139
- Issue
- 6
- Pages
- 719-27
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2130925114
- Cited by
- 363
- References
- 33
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.